Document Detail

Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney.
MedLine Citation:
PMID:  12682064     Owner:  NLM     Status:  MEDLINE    
Ischemic preconditioning renders the mouse kidney resistant to subsequent ischemia. Understanding the mechanisms responsible for ischemic preconditioning is important for formulating therapeutic strategies aimed at mimicking protective mechanisms. We report that the resistance afforded by 30 min of bilateral kidney ischemia persists for 12 weeks after preconditioning. The protection is reflected by improved postischemic renal function, reduced leukocyte infiltration, reduced postischemic disruption of the actin cytoskeleton, and reduced postischemic expression of kidney injury molecule-1 (Kim-1). The protection is observed in both BALB/c and C57BL/6J strains of mice. Thirty minutes of prior ischemia increases the expression of inducible nitric-oxide synthase (iNOS) and endothelial NOS (eNOS) and the expression of heat shock protein (HSP)-25 and is associated with increased interstitial expression of alpha-smooth muscle actin (alpha-SMA), an indication of long term postischemic sequelae. Treatment with Nomega-nitro-l-arginine (l-NNA), an inhibitor of NO synthesis, increases kidney susceptibility to ischemia. Gene deletion of iNOS increases kidney susceptibility to ischemia, whereas gene deletion of eNOS has no effect. Pharmacological inhibition of NOS by l-NNA or l-N6-(1-iminoethyl) lysine (l-NIL, a specific inhibitor of iNOS) mitigates the kidney protection afforded by 30 min of ischemic preconditioning. Fifteen minutes of prior ischemic preconditioning, which does not result in the disruption of the actin cytoskeleton, impairment of renal function, increased interstitial alpha-SMA, or increased iNOS or eNOS expression, but does increase HSP-25 expression, partially protects the kidney from ischemia on day 8 via a mechanism that is not abolished by l-NIL treatment. Thus, iNOS is responsible for a significant component of the long term protection afforded the kidney by ischemic preconditioning, which results in persistent renal interstitial disease, but does not explain the preconditioning seen with shorter periods of ischemia.
Kwon Moo Park; Ji-Yeon Byun; Cornelis Kramers; Jee In Kim; Paul L Huang; Joseph V Bonventre
Related Documents :
19366374 - Activation of tolloid-like 1 gene expression by the cardiac specific homeobox gene nkx2-5.
15911074 - Atrial natriuretic peptide in hypoxia.
15698834 - Expression of multiple kcne genes in human heart may enable variable modulation of i(ks).
1569934 - Identification and characterization of a cardiac-specific transcriptional regulatory el...
14969494 - Graphical exploration of gene expression data: a comparative study of three multivariat...
2423504 - Osmoregulation of the maltose regulon in escherichia coli.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2003-04-07
Journal Detail:
Title:  The Journal of biological chemistry     Volume:  278     ISSN:  0021-9258     ISO Abbreviation:  J. Biol. Chem.     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-07-14     Completed Date:  2003-08-27     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  2985121R     Medline TA:  J Biol Chem     Country:  United States    
Other Details:
Languages:  eng     Pagination:  27256-66     Citation Subset:  IM    
Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Actins / metabolism
Arginine / pharmacology
Cytoskeleton / metabolism
Enzyme Inhibitors / pharmacology
Heat-Shock Proteins*
Ischemic Preconditioning*
Kidney / blood supply*,  drug effects,  enzymology*,  injuries
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Neoplasm Proteins / metabolism
Nitric Oxide Synthase / antagonists & inhibitors,  deficiency,  genetics,  metabolism*
Nitric Oxide Synthase Type II
Nitric Oxide Synthase Type III
Nitroarginine / pharmacology
Reperfusion Injury / drug therapy,  enzymology,  prevention & control
Grant Support
Reg. No./Substance:
0/Actins; 0/Enzyme Inhibitors; 0/Heat-Shock Proteins; 0/Hspb1 protein, mouse; 0/Neoplasm Proteins; 2149-70-4/Nitroarginine; 74-79-3/Arginine; EC Oxide Synthase; EC Oxide Synthase Type II; EC Oxide Synthase Type III; EC protein, mouse; EC protein, mouse

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated ma...
Next Document:  Insight into the role of Escherichia coli MobB in molybdenum cofactor biosynthesis based on the high...